RxDoctor Payments Data

Mohd Hossain, MD

Internal Medicine · Hollis, NYNPI 1083931919

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 71 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$221
  • Bayer$207
  • Abbott$157
  • Lilly USA, LLC$153
  • Exact Sciences$148
  • Shield Therapeutics Inc$113
  • plus $585 from 13 others

What the payments were for

  • Food & beverage$1,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,585 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,208
Medicare patients
133
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin266$245,442
JanuviaSitagliptin Phosphate276$212,899
Diclofenac Sodium111$91,765
KerendiaFinerenone109$89,635
FarxigaDapagliflozin Propanediol102$86,067
JanumetSitagliptin Phos/Metformin Hcl88$75,890
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate24$66,636
Lactulose41$60,434
LinzessLinaclotide62$41,067
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog101$38,599
TradjentaLinagliptin47$30,941
TrulicityDulaglutide23$30,104
OzempicSemaglutide20$23,532
EntrestoSacubitril/Valsartan21$19,804
Diclofenac Potassium12$16,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$207$89,635109 claims
AstraZenecaFarxiga$94$86,067102 claims
AbbVieLinzess$87$41,06762 claims
Lilly USA, LLCTrulicity$153$30,10423 claims
Novo NordiskOzempic$44$23,53220 claims
GSKBreo Ellipta$69$5,64011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hollis

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →